After a 60-year scientific quest, the world has its first vaccine to protect against respiratory syncytial virus, or RSV -- and more are on the way. On Wednesday, the US Food and Drug Administration ...

According to the FDA, Arexvy reduced the risk of developing RSV-associated LRTD by 82.6% and severe RSV-associated LRTD by 94.1%. After decades of scientific research, the first vaccine for ...

Merck (NYSE:MRK) announced on Friday that an expert panel of the EU drug regulator, the European Medicines Agency (EMA), endorsed Enflonsia, a prophylactic antibody therapy developed by the company to ...

Merck Receives Positive EU CHMP Opinion for ENFLONSIA™ (clesrovimab) for the Prevention of Respiratory Syncytial Virus (RSV) in Infants During Their First RSV Season If approved by the European ...